2025-05-14T10:19:52-05:00 2024-06-30 390859910 BAKER TILLY ADVISORY GROUP LP 1570 FRUITVILLE PIKE SUITE 400 LANCASTER PA 17601 990 2023-07-01 210672684 CORIELL INSTITUTE FOR MEDICAL RESEARCH INC CORI 8567574828 403 HADDON AVENUE CAMDEN NJ 08103 DENISE L BUSCHER CFO 8567574828 2025-05-13 1 1 KERRI N BOGDA CPA P00760402 7177404863 2025-05-09 2023 2025-03-06 01:10:19Z DR JEAN-PIERRE ISSA 403 HADDON AVENUE CAMDEN NJ 08103 32105229 0 X WWW.CORIELL.ORG X 1953 NJ GENERATE WORLD CLASS BIOMATERIALS AND CONDUCT GROUNDBREAKING RESEARCH. 18 17 136 17 0 0 2510168 8141077 20786182 23813715 104954 147488 11087 2949 23412391 32105229 0 32900 0 0 11030292 11853540 0 0 0 11266445 12308126 22296737 24194566 1115654 7910663 29676741 33636721 6863084 2999544 22813657 30637177 X CORIELL'S MISSION IS TO ACCELERATE SCIENTIFIC DISCOVERY BY GENERATING, BANKING, STORING AND DISTRIBUTING WORLD-CLASS BIOMATERIALS, AND CONDUCTING GROUNDBREAKING RESEARCH IN GENETICS AND EPIGENETICS. 1 0 18571468 32900 23813715 THE CORIELL INSTITUTE FOR MEDICAL RESEARCH IS A GLOBALLY RECOGNIZED LEADER IN BIOBANKING AND BIOMEDICAL RESEARCH. CORIELL IS HOME TO ONE OF THE WORLD'S MOST IMPORTANT BIOBANKS WHICH DISTRIBUTES BIOLOGICAL SAMPLES AND OFFERS RESEARCH AND BIOBANKING SERVICES TO SCIENTISTS AROUND THE WORLD. CORIELL IS THE TRUSTED STEWARD OF WORLD-RENOWNED COLLECTIONS FOR THE NATIONAL INSTITUTES OF HEALTH, DISEASE FOUNDATIONS AND COMMERCIAL CLIENTS. IN ADDITION, AS A LEADER IN GENOMIC AND EPIGENOMIC RESEARCH, CORIELL IS UNCOVERING WAYS OR GENETIC MAKEUP AFFECTS OUR HEALTH, ESPECIALLY IN REGARD TO CANCER AND AGING. 191184 ON MARCH 1, 2023, THE INSTITUTE ENTERED INTO AN AGREEMENT WITH ROWAN UNIVERSITY, OF NEW JERSEY (ROWAN) AND THE COOPER HEALTH SYSTEM (COOPER), TO CREATE, COLLECTIVELY, THE CAMDEN CANCER RESEARCH CENTER (THE CENTER). THE AGREEMENT IS INTENDED TO CREATE A COLLABORATIVE JOINT VENTURE AMONG CAMDEN BASED INSTITUTIONS TO FURTHER EFFORTS TO FIND NEW TREATMENTS AND IMPROVE CURE RATES FOR CANCER PATIENTS, BOTH IN THE COMMUNITIES PRIMARILY SERVED BY THE CENTER AND FOR THE GENERAL PUBLIC AT LARGE. ADDITIONALLY, THE CENTER INTENDS TO DEVELOP THE INFRASTRUCTURE AND RESEARCH INITIATIVES THAT WILL ENABLE THE CENTER TO OBTAIN NATIONAL CANCER INSTITUTE (NCI) CONSORTIUM DESIGNATION IN COLLABORATION WITH ONE OR MORE NCI DESIGNATED CANCER CENTERS. 18762652 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 39 0 136 1 0 0 0 0 0 0 0 0 0 0 0 0 X 18 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NJ PA NY CA X HEATHER WHITE CONTROLLER 8567579738 403 HADDON AVENUE CAMDEN NJ 08103 DR JEAN-PIERRE ISSA PRESIDENT/CEO 40.00 0.00 X X 718898 0 54762 ROBERT KIEP III CHAIR 1.00 0.00 X X 0 0 0 MARC MASER ESQ VICE CHAIR 1.00 0.00 X X 0 0 0 JOHN APATHY MBA TRUSTEE 1.00 0.00 X 0 0 0 ARNAUD BASTIEN MD TRUSTEE 1.00 0.00 X 0 0 0 LOU BEZICH MPP TRUSTEE 1.00 0.00 X 0 0 0 PETER DRISCOLL ESQ TRUSTEE 1.00 0.00 X 0 0 0 CHRISTOPHER GIBSON ESQ TRUSTEE 1.00 0.00 X 0 0 0 FRANK GIORDANO TRUSTEE 1.00 0.00 X 0 0 0 GENEROSA GRANA MD FACP TRUSTEE 1.00 0.00 X 0 0 0 MATTHEW HEWITT PHD TRUSTEE 1.00 0.00 X 0 0 0 JOHN PICCONE TRUSTEE 1.00 0.00 X 0 0 0 ANNETTE REBOLI TRUSTEE 1.00 0.00 X 0 0 0 MIRUNA SASU PHD TRUSTEE 1.00 0.00 X 0 0 0 ROLAND SCHWARTING MD TRUSTEE 1.00 0.00 X 0 0 0 KENNETH SOMBERG MD MBA TRUSTEE 1.00 0.00 X 0 0 0 ANTONIO TILLIS PHD TRUSTEE 1.00 0.00 X 0 0 0 EDWARD VINER MD TRUSTEE 1.00 0.00 X 0 0 0 CONSTANTINE DEAN STOIOS CFO/SVP (UNTIL 09/23) 40.00 0.00 X 179500 0 45620 DENISE BUSCHER CFO 40.00 0.00 X 164411 0 18215 NAHID TURAN CHIEF BIOBANKING OFFICER 40.00 0.00 X 200468 0 51833 JAROLAV JELINEK CHIEF SCIENTIFIC OFFICER 40.00 0.00 X 201562 0 38768 LEO JOSE CIO & VP, INNOVATION 40.00 0.00 X 221182 0 23428 COURTNEY DIRKS SR DIR., PUB. RELATIONS (UNTIL 04/24) 40.00 0.00 X 196188 0 56605 RUTHSABEL O'LEXY DIR., RESEARCH OFFICE (UNTIL 04/24) 40.00 0.00 X 161922 0 16589 RYAN CUNNINGHAM DIRECTOR, FINANCE 40.00 0.00 X 151911 0 40770 JIAN HUANG ASSOCIATE PROFESSOR 40.00 0.00 X 146073 0 43067 JOHN LU APPLICATION DEVELOPER 40.00 0.00 X 136389 0 33612 2478504 0 423269 26 0 1 0 FIFTEEN AD LLC 28 N 3RD ST 4R PHILADELPHIA PA 19106 ARCHITECTURE SERVICES 1488946 VAN ANDEL INSTITUTE 333 BOSTWICK AVENUE NE GRAND RAPIDS MI 49503 NCI P50 SUBAWARD - RESEARCH/LAB WORK 505862 PENNONI ASSOCIATES INC PO BOX 827328 PHILADELPHIA PA 19182 ENGINEERING SERVICES 318110 ARCHER & GREINER 1025 LAUREL OAK ROAD VOORHEES NJ 08043 LEGAL SERVICES 308122 SCHEER PARTNERS INC 15245 SHADY GROVE RD 210 ROCKVILLE MD 20850 PROPERTY MANAGEMENT SERVICES 273138 14 1579 8021863 117635 8141077 GOVT FEES & CONTRACTS 621500 19784913 19784913 NON-GOVERNMENT REPOSITORY SERVICE 621500 3425851 3425851 INVESTIGATOR DIRECTED SCIENCE 621500 602951 602951 23813715 147488 147488 MISCELLANEOUS INCOME 900099 2949 2949 2949 32105229 23813715 0 150437 X 32900 32900 1834352 1834352 7154197 6685124 469073 512467 451811 60656 1691717 1691717 660807 504055 156752 163430 163430 89560 89560 115012 115012 3766318 2841421 924897 816941 804684 12257 4275511 3046542 1228969 198076 73969 124107 1227347 974952 252395 LAB SUPPLIES 1655479 1655025 454 GENOTYPING SUPPLIES 452 452 24194566 18762652 5431914 0 1200 1277 202792 4872858 3045757 3649087 1785356 1546391 306220 120095 61130 314083 485785 39341993 28969793 9598687 10372200 3197156 3634129 300000 0 11111615 8707644 29676741 33636721 2138788 1312967 38237 51271 4675500 0 10559 1635306 6863084 2999544 X 14191772 21791875 8621885 8845302 22813657 30637177 29676741 33636721 X 7910663 347979 -435122 X 0 1 X 1 0 X 1005217 1087567 3217491 2510168 8141077 15961520 1005217 1087567 3217491 2510168 8141077 15961520 134577 15826943 67021 62800 83936 92716 147488 453961 918 532774 77704 11087 2949 625432 17040913 95135474 0.92880 0.87100 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2019 AMOUNT: $ 918. 2020 AMOUNT: $ 532,774. 2021 AMOUNT: $ 77,704. 2022 AMOUNT: $ 11,087. 2023 AMOUNT: $ 2,949. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 115012 115012 24076554 24191566 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 66438 67900 67400 115012 316750 250000 250000 250000 250000 1000000 1500000 3197157 436973 3634130 3387810 309347 500000 3197157 3188112 350000 -150302 3387810 1837972 855673 494467 3188112 2002448 3148 -167624 1837972 0.30300 0.22470 0.47230 0 0 245000 245000 20290244 13641654 6648590 1725594 1655622 69972 17009360 13672517 3336843 71795 71795 10372200 USE OF RESEARCH FACILITY 5710635 SPLIT-INTEREST AGREEMENTS 522841 OTHER MISCELLANEOUS ASSETS 4185 PREPAID CAPITAL CONTRIBUTIONS 32863 RESTRICTED CASH 2437120 8707644 ADVANCES ON HAND 10127 HOLDING ACCOUNTS 432 DUE TO COLLABORATION PARTIES 1624747 1635306 X 32670361 347979 652275 -435122 565132 32105229 0 32105229 24846841 652275 652275 24194566 0 24194566 PART V, LINE 4: THE INSTITUTE'S ENDOWMENT FUNDS ARE USED TO SUPPORT THE SHORT AND LONG TERM GOALS OF THE INSTITUTE. PART X, LINE 2: THE INSTITUTE ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES USING A RECOGNITION THRESHOLD OF MORE LIKELY THAN NOT TO BE SUSTAINED UPON EXAMINATION BY THE APPROPRIATE TAXING AUTHORITY. MEASUREMENT OF THE TAX UNCERTAINTY OCCURS IF THE RECOGNITION THRESHOLD HAS BEEN MET. MANAGEMENT DETERMINED THAT THERE WERE NO TAX UNCERTAINTIES THAT MET THE RECOGNITION THRESHOLD IN 2024 AND 2023. 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 567415 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 1369426 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 51230 NORTH AMERICA 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 104348 SOUTH AMERICA 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 17534 SOUTH ASIA 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 25310 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 5646 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANT RESEARCH SUB-AWARD 32900 0 0 0 0 0 0 2173809 0 2173809 RESEARCH SUB-AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 32900 0 0 0 0 0 0 PART I, LINE 2: GRANTS FUNDS FOR THE SUB-AWARD WERE MONITORED THROUGH THE USE OF REPORTS PROVIDED BASED UPON THE WORK PERFORMED. X X 1 1 X X X X 0 0 0 0 0 0 0 1 0 DR JEAN-PIERRE ISSA PRESIDENT/CEO 555730 0 160000 0 3168 0 23100 0 31662 0 773660 0 0 0 COURTNEY DIRKS SR DIR., PUB. RELATIONS (UNTIL 04/24 176549 0 19254 0 385 0 13001 0 43604 0 252793 0 0 0 NAHID TURAN CHIEF BIOBANKING OFFICER 194622 0 5206 0 640 0 14180 0 37653 0 252301 0 0 0 LEO JOSE CIO & VP, INNOVATION 215495 0 5000 0 687 0 15190 0 8238 0 244610 0 0 0 JAROLAV JELINEK CHIEF SCIENTIFIC OFFICER 191686 0 5000 0 4876 0 13754 0 25014 0 240330 0 0 0 CONSTANTINE DEAN STOIOS CFO/SVP (UNTIL 09/23) 178718 0 0 0 782 0 13015 0 32605 0 225120 0 0 0 RYAN CUNNINGHAM DIRECTOR, FINANCE 146669 0 5000 0 242 0 10580 0 30190 0 192681 0 0 0 JIAN HUANG ASSOCIATE PROFESSOR 145390 0 0 0 683 0 10412 0 32655 0 189140 0 0 0 DENISE BUSCHER CFO 161028 0 2000 0 1383 0 11224 0 6991 0 182626 0 0 0 RUTHSABEL O'LEXY DIR., RESEARCH OFFICE (UNTIL 04/24) 155416 0 6226 0 280 0 10831 0 5758 0 178511 0 0 0 JOHN LU APPLICATION DEVELOPER 129735 0 5550 0 1104 0 9247 0 24365 0 170001 0 0 0 PART I, LINE 1A JEAN PIERRE ISSA, JAROSLAV JELINEK, NAHID TURAN, JOHN LU AND RUTHSABEL O'LEXY RECEIVED TAX GROSS-UP PAYMENTS RELATED TO SERVICE AWARDS AND BONUSES RECEIVED. ALL AMOUNTS ARE INCLUDED AS TAXABLE COMPENSATION. JAROSLAV JELINEK AND NAHID TURAN HAVE DISCRETIONARY SPENDING ACCOUNTS TO BE UTILIZED FOR BUSINESS PURPOSES ONLY AND FOLLOWING ALL NORMAL PURCHASING/TRAVEL POLICIES OF THE ORGANIZATION. THESE ACCOUNTS CANNOT BE USED FOR PERSONAL EXPENSES. PART I, LINE 7 THE COMPENSATION COMMITTEE DETERMINES BONUSES FOR OFFICERS AND KEY EMPLOYEES BASED UPON VARIOUS PERFORMANCE CRITERIA. PERFORMANCE CRITERIA ARE BASED ON VARIOUS OBJECTIVES, SOME OF WHICH ARE BASED ON BUSINESS/ FINANCIAL GOALS. OVERALL, THE PRIMARY OBJECTIVES ARE OPERATIONAL IN NATURE WITH CONSIDERATION GIVEN TO FINANCIAL OUTCOMES. FORM 990, PART III, LINE 2 ON MARCH 1, 2023, THE INSTITUTE ENTERED INTO AN AGREEMENT WITH ROWAN UNIVERSITY, OF NEW JERSEY (ROWAN) AND THE COOPER HEALTH SYSTEM (COOPER), TO CREATE, COLLECTIVELY, THE CAMDEN CANCER RESEARCH CENTER (THE CENTER). THE AGREEMENT IS INTENDED TO CREATE A COLLABORATIVE JOINT VENTURE AMONG CAMDEN BASED INSTITUTIONS TO FURTHER EFFORTS TO FIND NEW TREATMENTS AND IMPROVE CURE RATES FOR CANCER PATIENTS, BOTH IN THE COMMUNITIES PRIMARILY SERVED BY THE CENTER AND FOR THE GENERAL PUBLIC AT LARGE. ADDITIONALLY, THE CENTER INTENDS TO DEVELOP THE INFRASTRUCTURE AND RESEARCH INITIATIVES THAT WILL ENABLE THE CENTER TO OBTAIN NATIONAL CANCER INSTITUTE (NCI) CONSORTIUM DESIGNATION IN COLLABORATION WITH ONE OR MORE NCI DESIGNATED CANCER CENTERS. FORM 990, PART VI, SECTION A, LINE 1A THERE ARE 9 BOARD MEMBERS ON THE EXECUTIVE COMMITTEE. WITH THE EXCEPTION OF THE PRESIDENT AND CEO, THE OTHER BOARD MEMBERS OF THE EXECUTIVE COMMITTEE ARE NON-EMPLOYED VOLUNTARY BOARD MEMBERS. THE EXECUTIVE COMMITTEE MAY ACT ON BEHALF OF THE BOARD OF TRUSTEES WHEN THE BOARD IS NOT IN SESSION. FORM 990, PART VI, SECTION B, LINE 11B THE CFO PERFORMS AN INITIAL REVIEW OF THE FORM 990. AFTER INTERNAL REVIEW, THE CFO WILL PROVIDE THE DRAFT FORM 990 TO THE AUDIT COMMITTEE. FOLLOWING THE REVIEW BY THE AUDIT COMMITTEE THE FORM IS DISTRIBUTED TO ALL CORIELL TRUSTEES BEFORE FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE CEO ANNUALLY DISTRIBUTES THE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH MEMBER OF THE BOARD OF TRUSTEES. EACH TRUSTEE MUST COMPLETE AND RETURN THE ANNUAL DISCLOSURE STATEMENT TO THE CEO ON A TIMELY BASIS. HE OR SHE MUST TIMELY INFORM THE CEO AND/OR THE COMMITTEE OF ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST OR OF ANY SITUATION WHICH MIGHT LEAD TO THE APPEARANCE OF A CONFLICT OF INTEREST. IN ADDITION, THE CHIEF FINANCIAL OFFICER (CFO) ANNUALLY DISTRIBUTES A COPY OF THE EMPLOYEE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH OFFICER, EXECUTIVE, AND APPROPRIATE EMPLOYEE. THESE EMPLOYEES ARE REQUIRED TO SUBMIT THE COMPLETED DISCLOSURE STATEMENT TO THE CFO AND DISCLOSE ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST. REPORTED CONFLICTS OF INTEREST ARE SHARED WITH THE EXECUTIVE COMMITTEE. ANY BOARD MEMBER WHO HAS A CONFLICT OF INTEREST IS EXCLUDED FROM VOTING ON ANY ISSUE INVOLVING THE CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 USING COMPARABILITY DATA SOURCED FROM AN INDEPENDENT ORGANIZATION, A BOARD OF TRUSTEES' COMPENSATION COMMITTEE REVIEWS THE PERFORMANCE AND ESTABLISHES THE ANNUAL COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER. COMPENSATION DECISIONS ARE DETERMINED BY TAKING INTO CONSIDERATION THE FAIR MARKET RANGE FOR THE INDUSTRY. ALL COMMITTEE DISCUSSIONS ARE DOCUMENTED IN BOARD MINUTES. THE PRESIDENT DETERMINES THE COMPENSATION ANNUALLY FOR ALL OTHER EMPLOYEES, INCLUDING OFFICERS AND KEY EMPLOYEES, BASED ON PERFORMANCE APPRAISALS AND REVIEWS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 2,755,050. MANAGEMENT AND GENERAL EXPENSES 367,248. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 3,122,298. ADMINISTRATIVE COSTS: PROGRAM SERVICE EXPENSES 86,371. MANAGEMENT AND GENERAL EXPENSES 557,649. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 644,020. FORM 990, PART XI, LINE 9: CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 32,220. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -167,342. CORIELL LIFE SCIENCES NONCONTROLLING INTERESTS -300,000. CORIELL LIFE SCIENCES 403 HADDON AVENUE CAMDEN NJ 08103 461794812 GENETIC DATA STORAGE AND INTERPRETATION DE N/A C -875346 398625 0.39880 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 1 0 0